Expedited liver transplantation as first‐line therapy for severe alcohol hepatitis: ELFSAH; deferring corticosteroids in the sickest subset of patients DOI Creative Commons
Nabeeha Mohy‐ud‐din, Fei‐Pi Lin, Vikrant Rachakonda

et al.

Clinical Transplantation, Journal Year: 2024, Volume and Issue: 38(7)

Published: July 1, 2024

Severe alcohol-associated hepatitis (SAH) represents a lethal subset of liver disease. Although corticosteroids are recommended by guidelines, their efficacy and safety remain questionable so transplantation (LT) has been increasingly utilized. The timing indication corticosteroid use, specifically in patients being considered for LT requires further clarification.

Language: Английский

Research Priorities and Future Landscape of Clinical Trials in Alcohol-Associated Liver Disease DOI
Anand V. Kulkarni,

Ashwani K. Singal,

Patrick S. Kamath

et al.

Clinics in Liver Disease, Journal Year: 2024, Volume and Issue: 28(4), P. 831 - 851

Published: July 24, 2024

Language: Английский

Citations

1
Impact of Karnofsky performance status on outcomes of patients with severe alcohol‐associated hepatitis: a propensity‐matched analysis DOI Open Access
Anand V. Kulkarni, Shantan Venishetty, Karan Kumar

et al.

Internal Medicine Journal, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 27, 2024

Abstract Background and Aims Severity scores, including the model for end‐stage liver disease (MELD) discriminant function score, guide treatment of patients with severe alcohol‐associated hepatitis (AH). We aimed to investigate impact functional status on outcomes AH. Methods Medically managed ( n = 133) AH from 1 January 2019 31 December 2022 were included in this prospective study. The objectives compare long‐term survival, recompensation rates, corticosteroid response, incidence infections, hepatic encephalopathy (HE) acute kidney injury (AKI) among propensity score‐matched good Karnofsky performance (KPS) (score ≥50) poor KPS <50) using Kaplan–Meier analysis. Results Twenty‐five matched 25 followed up a median duration 10 (0.5–33) months. Survival was 76% (19/25; 95% confidence interval (CI), 54.9–90.6) compared 42.3% (11/25; CI, 23.4–63.1) P 0.001) at rate higher group than (68% vs 44%; 0.04). A proportion (78.9%) (42.8%; 0.03) responded corticosteroids. lower non‐responders (0% 75%; 0.01). who developed infection (36% 28%; 0.051), HE 12%; 0.01) AKI (60% 16%; < KPS. Conclusions is an important determinant AH, recompensation, response corticosteroids complications.

Language: Английский

Citations

1
Role of Prophylactic Antibiotics in Patients with Severe Alcohol-related Hepatitis DOI Open Access
Anand V. Kulkarni, Karan Kumar, Juan Pablo Arab

et al.

Journal of Clinical and Experimental Hepatology, Journal Year: 2023, Volume and Issue: 13(6), P. 1146 - 1148

Published: Nov. 1, 2023

Language: Английский

Citations

2
Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices DOI
Ashok Choudhury, Gupse Adalı, Apichat Kaewdech

et al.

Journal of Clinical and Experimental Hepatology, Journal Year: 2024, Volume and Issue: 14(3), P. 101347 - 101347

Published: Jan. 26, 2024

Language: Английский

Citations

0
Expedited liver transplantation as first‐line therapy for severe alcohol hepatitis: ELFSAH; deferring corticosteroids in the sickest subset of patients DOI Creative Commons
Nabeeha Mohy‐ud‐din, Fei‐Pi Lin, Vikrant Rachakonda

et al.

Clinical Transplantation, Journal Year: 2024, Volume and Issue: 38(7)

Published: July 1, 2024

Severe alcohol-associated hepatitis (SAH) represents a lethal subset of liver disease. Although corticosteroids are recommended by guidelines, their efficacy and safety remain questionable so transplantation (LT) has been increasingly utilized. The timing indication corticosteroid use, specifically in patients being considered for LT requires further clarification.

Language: Английский

Citations

0